MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 565652 | Name: STAD-2

Description:

WARNING: This product is for research use only, not for human or veterinary use.

STAD-2 is a cell permeable akap disruptor, selectively binding to pka-rii and blocking the interaction of pka-ri with akap

Chemical Structure

STAD-2
CAS#1542100-77-5

Theoretical Analysis

MedKoo Cat#: 565652

Name: STAD-2

CAS#: 1542100-77-5

Chemical Formula: C102H182N24O22

Exact Mass: 2095.3861

Molecular Weight: 2096.72

Elemental Analysis: C, 58.43; H, 8.75; N, 16.03; O, 16.79

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
STAD-2; STAD 2; STAD2
IUPAC/Chemical Name
(2S,5S,8S,11S,20S,E)-20-((2S,5S,8S,11S,14S,17S,20S,23S,26S)-38-amino-14,23,26-tris(4-aminobutyl)-11-benzyl-2-(hydroxymethyl)-8,20-diisobutyl-5-isopropyl-17-methyl-4,7,10,13,16,19,22,25,28-nonaoxo-30,33,36-trioxa-3,6,9,12,15,18,21,24,27-nonaazaoctatriacontanamido)-8-(4-aminobutyl)-N-((S)-1-(((S)-1-(((S)-1,6-diamino-1-oxohexan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)amino)-1-oxopropan-2-yl)-5-isobutyl-2,11,20-trimethyl-3,6,9,21-tetraoxo-1,4,7,10-tetraazacyclohenicos-15-ene-11-carboxamide
InChi Key
FREADERNJMYCAI-LLUHBCIQSA-N
InChi Code
InChI=1S/C102H182N24O22/c1-62(2)55-76(120-90(135)74(40-26-33-47-106)116-88(133)72(38-24-31-45-104)113-82(128)61-148-54-53-147-52-51-146-50-49-108)91(136)110-67(11)85(130)115-73(39-25-32-46-105)89(134)122-80(59-70-35-21-20-22-36-70)94(139)121-79(58-65(7)8)95(140)124-83(66(9)10)98(143)123-81(60-127)97(142)126-102(15)43-29-19-17-16-18-28-42-101(14,99(144)111-68(12)86(131)118-77(56-63(3)4)92(137)114-71(84(109)129)37-23-30-44-103)125-96(141)75(41-27-34-48-107)117-93(138)78(57-64(5)6)119-87(132)69(13)112-100(102)145/h16-17,20-22,35-36,62-69,71-81,83,127H,18-19,23-34,37-61,103-108H2,1-15H3,(H2,109,129)(H,110,136)(H,111,144)(H,112,145)(H,113,128)(H,114,137)(H,115,130)(H,116,133)(H,117,138)(H,118,131)(H,119,132)(H,120,135)(H,121,139)(H,122,134)(H,123,143)(H,124,140)(H,125,141)(H,126,142)/b17-16+/t67-,68-,69-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,83-,101-,102-/m0/s1
SMILES Code
O=C([C@@](CCC/C=C/CCC[C@@]1(NC([C@H](CO)NC([C@H](C(C)C)NC([C@H](CC(C)C)NC([C@H](CC2=CC=CC=C2)NC([C@H](CCCCN)NC([C@H](C)NC([C@H](CC(C)C)NC([C@H](CCCCN)NC([C@H](CCCCN)NC(COCCOCCOCCN)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)C)(C)NC([C@H](CCCCN)NC([C@H](CC(C)C)NC([C@H](C)NC1=O)=O)=O)=O)N[C@@H](C)C(N[C@@H](CC(C)C)C(N[C@@H](CCCCN)C(N)=O)=O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 2,096.72 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Bendzunas NG, Dörfler S, Autenrieth K, Bertinetti D, Machal EMF, Kennedy EJ, Herberg FW. Investigating PKA-RII specificity using analogs of the PKA:AKAP peptide inhibitor STAD-2. Bioorg Med Chem. 2018 Mar 15;26(6):1174-1178. doi: 10.1016/j.bmc.2018.02.001. Epub 2018 Feb 12. PubMed PMID: 29449124; PubMed Central PMCID: PMC5844854. 2: Autenrieth K, Bendzunas NG, Bertinetti D Dr, Herberg FW Prof Dr, Kennedy EJ Prof Dr. Defining A-Kinase Anchoring Protein (AKAP) Specificity for the Protein Kinase A Subunit RI (PKA-RI). Chembiochem. 2016 Apr 15;17(8):693-697. doi: 10.1002/cbic.201500632. Epub 2015 Dec 17. PubMed PMID: 26611881; PubMed Central PMCID: PMC4836982. 3: Flaherty BR, Wang Y, Trope EC, Ho TG, Muralidharan V, Kennedy EJ, Peterson DS. The Stapled AKAP Disruptor Peptide STAD-2 Displays Antimalarial Activity through a PKA-Independent Mechanism. PLoS One. 2015 May 26;10(5):e0129239. doi: 10.1371/journal.pone.0129239. eCollection 2015. PubMed PMID: 26010880; PubMed Central PMCID: PMC4444124.